Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
So will any updates drop in June or July? Any Thoughts?
L@@k at RONN up 200% RSPI could be the next one to run 200%
All these stocks are a gamble. I don't need prevention.
Anyone trading penny stocks should know the risks of run-up and run-downs.
You cannot win it if you don't buy it.
You cannot lose it if you if you don't buy it.
Don't spend more than you can afford to lose. Take profits on the way up.
I try to prevent others being scammed like you!
Resident average downer. Jeff says shame on you at this point!
No he can not. That is why I have him on ignore
Jj you don’t seem to bring any good news here.
You seem stir up trouble to manipulate stockholders into doubting their own perceptions or understanding of RSPI
If you are a stockholder can you provide something good here?
I’m not doing either. I just like the GA members that are here
Yes. Patience is must. It will take but more time until next RS
Patience is a pre-requisite in the OTC for the most spectacular gains. Traders typically flip out early for merely a few ticks or fail to hold winners. How many stories just on this board of selling other pharmas right before that 50-100 fold rise!!
Combining PR and recent CEO interview it is both logical and likely they are currently pursuing JV/partnering with BP to open “purse strings” now to further the pain/epilepsy candidate and likely could see multiple paths or deals borne out of that substantial progress.
My perception is the tier 3 NIH trials are probably the final piece to determine how valuable the candidate is. Is the potential heading into human clinical trials “somewhat” promising or “confidently optimistic” better medication is in the works…
As discussed, this sneezes anything positive and it can run multi penny overnight. A significant BP deal can have this trading for nickels, dimes or more…
Alas patience can also be frustrating….
Agreed...
A measly $600k+ valuation for all the effort and pharma science to help patients with unmet needs. I suppose being under appreciated would make me mad too..
5 Million Market Cap puts this at .0065
10 Million Market Cap puts this at .013
Petty cash for most of the Pharma's out there.
Targeting several high profile markets in desperate need: opioid alternative-replacement, sleep apnea, epilepsy, to name a few.
Just one triggers 10-50 million imho.
Patience of Job to see where this goes.
Mad? lol….
The Wild West of the OTC playground. No 10-k, no 10-q, no speak. Yet lots of effort to set up OSA program in Australia and “remarkable” progress with their pain/epilepsy candidate in all kinds of preclinicals and robust NIH trials and only a few dozen message forum posters even are remotely interested…
A measly $600k+ valuation for all the effort and pharma science to help patients with unmet needs. I suppose being under appreciated would make me mad too..
Logic will probably dictate course correction or not….
JJ just buy them up or Sell or move on.
I don’t care who is mad.
Jeff has told me never use the stuff that you sell!!!
Help yourself then JJ. 9 is just a flip away from 6.
who stopped averaging down? Jeff is mad!!!!
Based on the wording in the last PR, it seems as though further development of their AMPA program is on hold pending funding. As you suggest it appears tricky to get these compounds to work at lowest dosage and no side effects. Guessing additional funding to support OSA program is a higher priority for various reasons.
This leaves the GABA program and KRM-II-81. How long do these tier 3 preclinicals take to look at more defined pain models and direct abuse liability? CEO said not quick, more intermediate type work. 4 months? 6+ months? Assuming they started to process in Q1, feels like they could be nearing some early indication results, although just a gut thought there, no idea how long the process could take...
Given the high profile nature of the opioid crisis, there is no way an under resourced OTC is gonna lead into human trials. Their filings essentially indicate that. Logically, it would make sense to bring the preclinical effort for KRM-II-81 to maturity, partner/JV going forward and use that value creation to further the OSA program in Australia. Until we begin to hear again from the company however, everything is pure speculation. Good luck to all.
Agreed. Reviewing all the published info about KRM-II-81, I think it has a chance to be just that. When the CEO stated it really is "remarkable" drug, I believe that is a genuine belief based upon what preclinical work has been indicating. Being effective against various forms of pain indications as well as epilepsy provides many possible paths of development that is most suitable for the candidate. IMO, they have to be getting closer to completing all the IND enabling preclinicals they could want. Maybe the purpose is to understand truly how valuable this "remarkable" drug candidate is. Given past preclincial success and progress within the NIH program, surely BP is watching this one close. The silence and lack of attention to investors only adds to the mystique surrounding all this.
“AMPA-glutamate receptors (AMPARs) are expressed throughout the CNS and mediate the majority of fast excitatory synaptic transmission. Ampakines are orally available small molecules that bind allosterically to AMPARs and enhance excitatory currents elicited by the endogenous agonist glutamate.
In preclinical studies, ampakines are effective in ameliorating symptoms in a battery of neurodegenerative and neuropsychiatric diseases in which excitatory transmission is compromised. However, the development of ampakines as medicines was slowed by the emergence of neurotoxicity and seizures in rodents due to some ampakines. Here, we describe the preclinical pharmacology of a novel ampakine, CX1739, that does not induce seizures in animals or humans at efficacious doses.
CX1739 dose-dependently enhanced long-term potentiation in vivo in rats, a process thought to be a molecular substrate of learning and memory. Correspondingly, CX1739 dose-dependently enhanced performance in assays that probed multiple aspects of cognition—the novel object recognition test, the winshift radial arm maze, and the five-choice serial reaction time task in rats. CX1739 also abrogated amphetamine-induced locomotor activity, demonstrating that it may be given in conjunction with stimulants for pro-cognitive gains while mitigating the side effects of stimulant-based ADHD medications. CX1739 also rapidly reversed opioid-induced respiratory depression. While efficacy in these tests occurred at doses of 0.03–18 mg/kg, there were no adverse events detected in safety studies in rats up to 2000 mg/kg.
These preclinical findings suggest that CX1739 can be translated safely into the clinical setting to potentially treat dementia, neuropsychiatric disorders, and the life-threatening complication of opiate-induced suppression of endogenous inspiratory breathing rhythms.”
But still the CX drugs are the “origin story” of this company.
Let me put it this way: ANY option that would help the opioid crisis AT ALL even if it only works “okay” or “sort of” would still be a blockbuster.
Yeah, I think I read that about the CX- in my DD review. I have not seen anything similar for KRM-II-81, not to say that it wont have any issues in human clinicals, but I think it is similar enough to current treatments only with much less deficiency in performance.
To me the most valuable programs in motion is the KRM-II-81 and then the OSA programs. BP/Funding is required to push these into human trials I believe. They seem to be having positive traction but who knows...
Maybe KRM-II-81 has had better oral availability, but the Ampakines had been beset by delivery and/or potency/toxicity issues since even when that company was called Cortex pharm. That was why the first batch of “CX-“ drugs were shut down. That is a key hint to make sense of that company’s history. The literature on CX compounds is surprisingly diverse and extensive, and goes back to the 1980s.
I was under the impression that they have tested the new OSA nano formulations to be able to meet their requirements to move forward into human trials. Although, maybe doing pre-clinical work currently?
With KRM-II-81, I think they have done many preclinicals and finishing up with NIH in preps for human clinicals. I am sure drug delivery efficiency plays a role in all trials for all drugs, but with the OSA drug nano technology can overcome the extended release requirements with low dosage.
It’s a much less trivial issue than that, actually very tricky to get working right.
The nanoparticles are multi-purpose, and my guess is that they will help address problems with all the compounds in RSPI’s pipeline. Why might that company carry on with such a seemingly diverse set of drug candidates? Drug delivery problems bind them!
I interpret the nanoparticles as necessary for OSA to extend the release or time period where dranabinol can impact OSA positively and without side effects to high doses.
I have not read where it would impact the other programs of RSPI. Overall, the capacity of nanoparticles to improve drug delivery for all drugs is something I would assume many BP is well versed in.
Nanoparticals in and of themselves improve the efficacious absorption for greater benefit + less negatives, like side effects?
Yeah I think specifically only the OSA program is part of the Australian sub. The AMPA and GABA programs stay under RespireRx. I am not sure there is much the Austalian sub can provide back to the AMPA and GABA programs. Both essentially just need money/partners to continue into human trials.
The specific competence that the Australian subsidiary brings to RespireRx is access to the manufacturing and testing of the lipid nanoparticule in situ drug delivery formulation. This is done in collaboration with a third party located also in Australia, Ab Initio.
Dronabinol is, if you want, incidental. The purpose is to harness the nanoparticles, which can be used with other compounds. Note that the particular challenge that the Ampakines drugs faced was effective delivery, since high potency versions had unacceptable side effects, while the gentler low potency drugs tended to not get to the target tissue in adequate amounts or timing. Such that the nanoparticles can rehabilitate the Ampakine pipeline. And the same holds for the GABAkines, i.e. KRM-II-81, and analogs.
“ the ability of KRM-II-81 to dramatically reduce epileptiform electrical activity when administered in situ.”
https://ab-initio-pharma.com/news/2023/10/13/ab-initio-signs-master-service-agreement-with-resolution-rx
RespireRx Pharmaceuticals Inc. (RSPI) has been involved in several key activities and updates in 2024:
Cannabinoid Confusion: There has been ongoing debate and confusion in the U.S. regarding cannabinoids. Despite this, RSPI’s Australian deal is considered financially sensible, although there has been no recent update on this matter.
Preclinical Progress: It is assumed that preclinical work with new formulations is in progress, but there has been no update on any FDA discussions or additional funding for their development path.
Drug Platforms: RSPI’s filings have suggested that all their drug programs should be partnered, joint-ventured, or sold. The status of one of the three main platforms could significantly impact the other two.
OSA Drug Development: For the OSA drug, RSPI is awaiting the manufacture of new formulations. With roughly half of the funding in place and intent to list on the ASX, they are a few steps away from clinical trials with the new formulations.
Clinical Trials for Other Candidates: The recent PR suggests that trials for the spinal and ADHD candidate might occur later this year, pending funding. The epilepsy/pain candidate drug is in tier 3 of NIH, and the CEO has indicated a short-term goal of securing funds to support it.
Stock Performance: There has been mention of dilution, but shares are considered tight as investors are believed to be absorbing available shares in numbers.
These updates reflect RSPI’s ongoing efforts in drug development and its strategic moves in the pharmaceutical industry. The company seems to be progressing towards clinical trials for its new formulations and seeking partnerships to advance its drug candidates.
ResolutionRx Ltd subsidiary of RespireRx Pharmaceuticals Inc.
Key details about the company:
Formation and Purpose: ResolutionRx Ltd was formed in Australia on January 11, 2023, as an unlisted public company by RespireRx.
The subsidiary was established with the aim of discovering and developing medicines for the treatment of psychiatric and neurological disorders.
Focus on Obstructive Sleep Apnea (OSA): ResolutionRx is particularly focused on treatments for sleep-related breathing disorders such as obstructive sleep apnea (OSA). OSA is a condition that affects millions of people worldwide and is associated with decreased quality of life and significant functional impairment.
Repurposing Dronabinol: The company is repurposing dronabinol for the treatment of OSA. Dronabinol was first approved in the United States in 1985 and is currently approved for anorexia associated with AIDS and chemotherapy-induced nausea and vomiting.
Financing Research and Development: ResolutionRx has entered into a Letter of Intent (LOI) and Term Sheet with Radium Capital to finance anticipated Research and Development Credits. This arrangement is designed to unlock research and development tax credits available in Australia.
Non-Dilutive Funding: The agreement with Radium Capital creates a means of realizing the Research and Development Tax Incentive (R&DTI) funds well in advance of the annual cash receipt from the Australian government. This provides a valuable non-dilutive means of supporting ResolutionRx’s R&D efforts towards the commercialization of dronabinol for the treatment of OSA.
ResolutionRx Ltd is actively working towards the development and commercialization of cannabinoids such as dronabinol for sleep-related and other breathing disorders, leveraging the support and resources provided by its parent company, RespireRx Pharmaceuticals Inc.
I believe that is inaccurate.
They only moved the OSA/cannaboids program to Australia only. The GABA program with KRM-II-81 is the one in NIH preclinical trials and has shown significant potential which hopefully leads to multiple development deals/paths for epilepsy and various forms of pain management. The CEO interview in March highlighted how confident they are becoming in this drug candidate as it is now in the final tier 3 stage of NIH where they are supposedly looking at specific pain models/indications and directly testing addictive liability in animals. If these results continue to confirm their past work and all inference studies, then this will be an absolute monster winner.
Timing of when they wrap up the tier 3 preclinicals is unknown, but the CEO implied it was an "intermediate" step and hoping to open pursestrings in the shorter term.
There are plans for clinical trials involving humans for KRM-II-81.
RespireRx Pharmaceuticals Inc. has reported that they are expanding the IND (Investigational New Drug) enabling studies in preparation to begin human studies. This is a significant step forward as it indicates that the compound has shown sufficient promise in preclinical studies to warrant further investigation in clinical settings.
The company has expressed excitement about the potential of KRM-II-81 to represent a breakthrough medication for pain, epilepsy, and other neuropsychiatric disorders, pending clinical validation. The advancement to human clinical trials is a critical phase in drug development, and it will provide more definitive evidence of the compound’s safety and efficacy in humans.
KRM-II-81 is a novel compound that has been making significant strides in medical research, particularly in the treatment of epilepsy and pain management. Here are some key points from the latest research in 2024:
Epilepsy Treatment: A case report published in Heliyon journal detailed the effects of KRM-II-81 on epileptiform activity in brain tissue surgically removed from a 19-year-old patient with pharmaco-resistant epilepsy. The compound, a GABA A receptor potentiator, successfully suppressed epileptiform bursting in the excised brain tissue. This finding supports the potential of KRM-II-81 to reduce seizure burden in patients resistant to standard anti-epileptic treatments.
Pain Management: KRM-II-81 has also been reported to show promise in preclinical pain relief studies. It has advanced to the next level of evaluation within the NIH HEAL Initiative® Preclinical Screening Platform for Pain (PSPP) program. The compound demonstrated the ability to block pain-like behaviors in rats without significant side effects, which is a crucial step towards developing non-opioid pain therapeutics.
Future Prospects: Although KRM-II-81 has shown efficacy comparable to diazepam in various animal models of epilepsy and pain, it has not yet undergone trials in humans. The ongoing research and development suggest that KRM-II-81 could potentially be a breakthrough medication for epilepsy, pain, and other neuropsychiatric disorders pending clinical validation.
These developments indicate a promising future for KRM-II-81 as a potential treatment option for conditions that currently have limited effective therapies.
American Chemical Association
https://pubs.acs.org/doi/10.1021/acsomega.2c03029
Is research going on with KRM-II-81 in Australia?
Yes, there is ongoing research involving KRM-II-81 in Australia.
RespireRx Pharmaceuticals Inc. has reported that as part of an ongoing collaboration, translational studies have demonstrated the ability of KRM-II-81 to dramatically reduce epileptiform electrical activity when administered in situ.
This suggests active preclinical research efforts are being conducted to further understand and develop KRM-II-81’s therapeutic potential.
For more detailed information on the specific nature of these studies or any collaborative efforts in Australia, it would be best to refer to the latest publications or announcements from RespireRx Pharmaceuticals Inc. or their research partners.
KRM-II-81 is a novel compound that acts as a positive allosteric modulator of the GABAA receptor.
It is particularly selective for the alpha2 and alpha3 subunits of this receptor.
The mechanism of action for KRM-II-81 involves enhancing the inhibitory effects of the neurotransmitter GABA (gamma-aminobutyric acid) at the GABAA receptors.
This modulation results in anxiolytic, antidepressant, and anticonvulsant effects.
Notably, KRM-II-81 has been shown to have fewer adverse effects compared to some other GABAA positive allosteric modulators (PAMs). It is associated with low to no sedation and does not lead to tolerance development, which are significant advantages over other similar compounds.
Additionally, KRM-II-81 has demonstrated effectiveness in treating seizures better than diazepam, a commonly used anticonvulsant, and has shown promise in pharmaco-resistant models of epilepsy. This makes it a potentially valuable addition to the treatment options for conditions that involve neuronal hyperexcitability, such as certain types of epilepsy.
As of the latest available information, KRM-II-81 has advanced to the next level of evaluation within the NIH HEAL Initiative®Preclinical Screening Platform for Pain (PSPP) program.
This program evaluates non-opioid assets in a battery of established preclinical pain models. The emerging data showed that KRM-II-81 blocked pain-like behaviors in rats with minimal or no detectable side effects.
While KRM-II-81 has shown promise in preclinical studies, including effectiveness in relieving acute, chronic, and neuropathic pain without tolerance development or sedation, it appears that it has not yet entered human clinical trials.
The RespireRx team is expanding the IND (Investigational New Drug) enabling studies to begin human studies.
Pending clinical validation, KRM-II-81 is believed to have the potential to be a breakthrough medication for pain, epilepsy, and other neuropsychiatric disorders.
RespireRx Pharmaceuticals Inc. is actively developing a diverse drug pipeline with a focus on disorders caused by the disruption of neuronal signaling.
Their pipeline includes:
Cannabinoid Platform:
Pharmaceutical Cannabinoids:
They are working on treatments for conditions like Obstructive Sleep Apnea, with Dronabinol being a key compound in development for this purpose.
Neuromodulators:
AMPAkines: This platform includes compounds like CX1739, which has shown promise in preclinical research for improving bladder function after spinal cord injury.
GABAkines: This platform is focused on developing non-opioid treatments for conditions such as epilepsy and pain.
Just seeing what I can find out there. Nothing new yet. 10Q needs filing
The last thing we know is the 8K filed on 4-16-2024 The exercise price is $0.0015 per share
tem 1.01 Entry into a Material Definitive Agreement.
Demand Promissory Note and Warrant Agreement
General
On April 10, 2024, the RespireRx Pharmaceuticals Inc. (“RespireRx” or the “Company”) entered into a Demand Promissory Note and Warrant Agreement (“Purchase Agreement”) and issued a demand promissory note (“Demand Promissory Note”) and a warrant (“Warrant”) associated with the Purchase Agreement. Pursuant to the Purchase Agreement, both RespireRx and the investor (“Investor”) made representations to one another including, but not limited to representations by RespireRx as to its the good standing, subject to any Delaware Franchise Tax that may remain due and payable as of the date of the Purchase Agreement, the authority and enforceability of the Purchase Agreement, non-contravention, litigation, title, intellectual property, and debt for borrowed money and representations by the Investor including, but not limited to the nature of the arrangement being a binding obligation, that the Investor had been advised that the securities have not been registered under the Securities Act of 1933, as amended (the “Securities Act”) or any state laws, that the Investor understands that there are restrictions on transfer, that the Investor has sufficient knowledge of financial and business matters and that the Investor is an accredited investor as defined in Rule 501 of Regulation D under the Securities Act. The forms of the Demand Promissory Note and the Warrant are Exhibits A and Exhibits B to the Purchase Agreement.
The Demand Promissory Note accrues interest at the rate of 10% per annum based on a 365/366 day year, as applicable. Principal and interest are payable on demand of the lender (“Lender”). Accrued unpaid interest is added to principal at the end of the year that principal is unpaid. Payments are applied first to interest and then principal. To secure its obligations under the Note and to induce the Lender to extend the loan (“Loan”) to RespireRx (“Borrower”), the Borrower granted, a security interest in and to, all of such Borrower’s right, title and interest in and to all of the property identified in the Note, provided, that to the extent that any of the Collateral is subject, prior to the date of the Borrower’s Note to a security interest in favor of a third party and the agreement with such third party expressly prohibits any grant of a security interest therein, the Borrower will not be deemed to have a security interest in such Collateral only for so long as such prohibition continues. The terms of the Purchase Agreement and the Warrant are governed by the laws of the State of New York, without giving effect to any choice or conflict of law provision or rule. The terms of the Note are governed by the laws of the State of Delaware, excluding rules related to conflicts of laws.
The Warrant is exercisable in whole or in part at any time from the issuance date (April 10, 2024) to the expiration date which is five years from the initial exercise date. The exercise price is $0.0015 per share of RespireRx’s common stock, par value $0.001 (“Common Stock”). The Warrant may be exercised by cashless exercise in accordance with a formula described in the Warrant. The number of shares of Common Stock into which the Warrant may exercise and the exercise price may be adjusted for capital reorganizations or reclassifications such as stock splits, reverse stock splits, stock dividends and similar capital reorganizations or reclassifications. The Warrant and the shares of Common Stock into which the Warrant may be exercised are subject to transfer restrictions. Certain representations were made by the Warrant holder.
Dariusz Nasiek and Sara Nasiek, JTTEN
The Purchase Agreement is with the Dariusz Nasiek and Sara Nasiek, JTTEN and identified a $100,000.00 loan in the form of a Demand Promissory Note and a Warrant exercisable into 33,333,333 shares of RespireRx Common Stock. Dariusz Nasiek is a member of the Board of Directors of the Company.
The above is a summary of what the Company believes are key the provisions of the Purchase Agreement, the Demand Promissory Note and the Warrant. A copy of the entirety of each is filed as Exhibits 10.1-10.3 to this Current Report on Form 8-K. The above summary is qualified in its entirety by this Current Report on Form 8-K including the copy of the Purchase Agreement, the Demand Promissory Note and the Warrant between Dariusz Nasiek and Sara Nasiek, JTTEN and RespireRx Pharmaceuticals Inc. dated April 10, 2024 filed as Exhibits 10.1-10.3 to such report.
Fast track. FDA..
Don’t get ahead. The shares sold pay the salaries.. consulting etc
Fast track. FDA..
Don’t get ahead. The shares sold pay the salaries.. consulting etc
I think there continues to be debate and plenty confusion in the US in regards to cannabinoids. The Australian deal makes sense financially for sure. We have not got an update there. Assuming preclinical work with the new formulations is in progress? No update on any FDA discussions or additional funding for their development path?
I think their filings for awhile have mentioned all their drug programs should be partnered/JV or sold. What happens to one of the three main platforms logically would significantly impact the other two. Maybe why everything seems to be frozen waiting for something to happen. No communications, no real trading volume or interest, no 10-k, just silence.
I agree. They look to historically struggle getting any funding for their programs. I think the point out of the NIH trials, is that if the final preclincals continue to point to human trials, then the NIH will be funding some of that via grants and I think the investment thesis is "purse strings" will open from BP to take the baton and run with it. Given the current published success with KRM-II-81 in preclinicals for a wide array of pain indications and epilepsy, the thought or maybe the "gamble" is there are various paths of development and partnerships possibly under consideration to move the ball forward. I would speculate all other drug development programs would be on hold until they have direction with this.
One has to admit the silence and lack of 10-k, and a BOD loan... considering the extremely positive progress with the NIH is a change in the status quo, ho hum OTC penny stock life. Could also be desperation. But in OTC world, there is a fine line and sudden switch possible between desperation and a 100 bagger... lol
Regardless of funding, it may have been the faster track to getting FDA approval if it's efficacy continues to be borne out?
They had to send a drug to Australia to get funding for phase III.. let that sink in. You think they can easily fund a pre clinical one?
My little order finally filled today. GLTA & Happy wknd! HB
No idea how that all works, but I think the CEO mentioned in interview they were being tested against various types of pain models. And of course you have epilepsy work which has also shown to be very positive in their trials. I can imagine drug development and Human trials to treat all these various medical indications would take multiple paths, many various human clinicals and would likely include various interested BP.
Followers
|
343
|
Posters
|
|
Posts (Today)
|
37
|
Posts (Total)
|
48123
|
Created
|
12/30/04
|
Type
|
Free
|
Moderators oldstocks DTGoody powerbattles fly_fisherman archilles jacksonjohn |
RespireRx Pharmaceuticals Inc. and its subsidiaries and business units are discovering and developing medicines for the treatment of psychiatric and neurological disorders, with a focus on treatments that address conditions affecting millions of people, but for which there are few or poor treatment options, including epilepsy, pain, attention deficit hyperactivity disorder (“ADHD”), recovery from spinal cord injury (“SCI”), certain neurological orphan diseases and obstructive sleep apnea (“OSA”). The RespireRx Group is developing a pipeline of new and repurposed drug products based on our broad patent portfolios for two drug platforms: (i) neuromodulators, which include GABAkines and AMPAkines, proprietary chemical entities that positively modulate (positive allosteric modulators or “PAMs”) GABAA receptors and AMPA-type glutamate receptors, respectively, and (ii) pharmaceutical cannabinoids, which include dronabinol, a synthetic compound that acts upon the nervous system’s endogenous cannabinoid receptors and
The RespireRx Group holds exclusive licenses and owns patents and patent applications or rights thereto for certain families of chemical compounds that claim the chemical structures and their uses in the treatment of a variety of disorders, as well as claims for novel uses of known drugs.
EndeavourRx: Neuromodulators
GABAkines. Under a License Agreement with the University of Wisconsin-Milwaukee Research Foundation, Inc. (“UWMRF”) and on behalf of its EndeavourRx business unit, RespireRx has licensed rights to certain selectively acting GABAkines because of their ability to selectively amplify inhibitory neurotransmission at a highly specific subset of GABAA receptors, thus producing a unique efficacy profile with reduced side effects. Preclinical studies have documented their efficacy in a broad array of animal models of interrelated neurological and psychiatric disorders including epilepsy, pain, anxiety, and depression in the absence of or with greatly reduced propensity to produce sedation, motor-impairment, tolerance, dependence and abuse. EndeavourRx currently is focusing on developing KRM-II-81 for the treatment of epilepsy and pain.
KRM-II-81 has displayed a high degree of anti-convulsant activity in a broad range of preclinical studies, including in treatment resistant and pharmaco-resistant models. Not only was KRM-II-81 highly effective in these models, but pharmaco-resistance or tolerance did not develop to its anti-convulsant properties. These latter results are particularly important because pharmaco-resistance occurs when medications that once controlled seizures lose efficacy as a result of chronic use and it is a principal reason some epileptic patients require brain surgery to control their seizures. In support of its potential clinical efficacy, translational studies have demonstrated the ability of KRM-II-81 to dramatically reduce epileptiform electrical activity when administered in situ to brain slices excised from treatment resistant epileptic patients undergoing surgery.
In addition, KRM-II-81 has displayed a high degree of analgesic activity in a broad range of preclinical studies. In intact animal models of pain, the analgesic efficacy of KRM-II-81 was comparable to or greater than commonly used analgesics. At the same time, KRM-II-81 did not display side effects such as sedation and motor impairment, but even more importantly, it did not produce tolerance, dependence, respiratory depression or behavioral changes indicative of abuse liability, which are produced by opioid narcotics and are at the heart of the opioid epidemic.
AMPAkines. Through an extensive translational research effort from the cellular level through Phase 2 clinical trials, RespireRx has developed a family of novel, low impact AMPAkines, including CX717, CX1739 and CX1942 that may have clinical application in the treatment of CNS-driven neurobehavioral and cognitive disorders, spinal cord injury, neurological diseases, and certain orphan indications. Our lead clinical compounds, CX717 and CX1739, have successfully completed multiple Phase 1 safety trials. Both compounds have also completed Phase 2 proof of concept trials demonstrating target engagement, by antagonizing the ability of opioids to induce respiratory depression.
AMPAkines have demonstrated positive activity in animal models of ADHD, results that have been extended translationally into statistically significant improvement of symptoms observed in a Phase 2 human clinical trial of CX717 in adult patients with ADHD. Statistically significant therapeutic effects were observed within one week. We believe AMPAkines may represent a novel, non-stimulant treatment for ADHD with a more rapid onset of action than alternative non-stimulants, such as Straterra® (atomoxetine), and without the drawbacks of amphetamine-type stimulants.
In a series of important studies funded by grants from the National Institutes of Health and published in a number of peer reviewed articles, Dr. David Fuller (University of Florida), a long-time RespireRx collaborator, has demonstrated the ability of CX1739 and CX717, RespireRx’s lead AMPAkines, to improve motor nerve activity and muscle function in a number of animal models of spinal cord injury (SCI).
FORM TYPE | RECEIVED | PERIOD END DATE | REPORT |
---|---|---|---|
8-K | 02/02/2024 | 01/30/2024 | PDFRTFHTMLXLS |
8-K | 01/22/2024 | 01/18/2024 | PDFRTFHTMLXLS |
8-K | 12/11/2023 | 12/06/2023 | PDFRTFHTMLXLS |
10-Q | 11/17/2023 | 09/30/2023 | PDFRTFHTMLXLS |
NT 10-Q | 11/14/2023 | 09/30/2023 | PDFRTFHTML |
8-K | 10/12/2023 | 10/09/2023 | PDFRTFHTMLXLS |
8-K | 10/02/2023 | 09/26/2023 | PDFRTFHTMLXLS |
10-Q | 08/21/2023 | 06/30/2023 | PDFRTFHTMLXLS |
NT 10-Q | 08/14/2023 | 06/30/2023 | PDFRTFHTML |
8-K | 08/09/2023 | 08/03/2023 | PDFRTFHTMLXLS |
DISCLAIMER:
Nothing in the contents transmitted on this board should be construed as an investment advisory, nor should it be used to make investment decisions.
There is no express or implied solicitation to buy or sell securities.
The author(s) may have positions in the stocks or financial relationships with the company or companies discussed and may trade in the stocks mentioned.
Readers are advised to conduct their own due diligence prior to considering buying or selling any stock.
All information should be considered for information purposes only.
No stock exchange has approved or disapproved of the information here
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |